Valuation: Aquestive Therapeutics, Inc.

Market Cap 532M 467M 430M 401M 755M 50.57B 771M 5.17B 2B 24.82B 2B 1.95B 86.39B P/E 2026 *
-10.5x
P/E 2027 * -10.9x
Enterprise Value 447M 392M 361M 337M 635M 42.49B 648M 4.34B 1.68B 20.86B 1.68B 1.64B 72.58B EV / Sales 2026 *
8.85x
EV / Sales 2027 * 7.4x
Free-Float
96.9%
Yield 2026 *
-
Yield 2027 * -
1 day+1.92%
1 week-15.03%
Current month+1.92%
1 month+6.00%
3 months+2.66%
6 months-34.37%
Current year-34.37%
1 week 4.1
Extreme 4.1
4.48
1 month 3.85
Extreme 3.85
5.18
Current year 2.93
Extreme 2.93
6.59
1 year 2.93
Extreme 2.93
7.55
3 years 1.25
Extreme 1.2514
7.55
5 years 0.62
Extreme 0.618
7.55
10 years 0.62
Extreme 0.618
20.7
Manager TitleAgeSince
Chief Executive Officer 50 17/05/2022
Director of Finance/CFO 67 31/12/2020
Compliance Officer - 02/04/2026
Director TitleAgeSince
Chairman 72 01/04/2024
Director/Board Member 60 01/01/2004
Director/Board Member 50 17/05/2022
Date Insider Type Main position Quantity % Market Cap.
06-23Fiscal year

Director

75,000 0.0598%
06-15Sell

Chief Executive Officer

-25,000 0.0199%
06-10Other

Chairman

50,500 0.0403%
Change 5-day change 1-year change 3-year change Capi.($)
+1.92%-15.03%+24.71%+156.97% 522M
-0.64%+6.67%+53.59%+154.11% 1,070B
+0.00%+5.39%+62.89%+53.44% 611B
-0.23%+6.88%+32.14%+86.34% 445B
-1.20%-0.96%+26.12%+20.22% 329B
-1.74%-0.40%+33.19%+22.86% 290B
-1.25%+0.53%+27.68%+38.89% 287B
+2.99%+4.00%-26.09%-41.06% 213B
-0.22%+2.82%+24.37%+62.75% 195B
-0.29%+0.65%+12.75%+63.45% 157B
Average -0.07%+0.84%+27.14%+61.80% 359.68B
Weighted average by Cap. -0.42%+4.20%+38.21%+76.15%

Financials

2026 *2027 *
Net sales 50.51M 44.35M 40.82M 38.04M 71.74M 4.8B 73.2M 491M 190M 2.36B 190M 186M 8.2B 71.92M 63.14M 58.12M 54.16M 102M 6.84B 104M 699M 271M 3.36B 270M 264M 11.68B
Net income -50.65M -44.47M -40.93M -38.14M -71.93M -4.82B -73.39M -492M -191M -2.36B -190M -186M -8.23B -47.99M -42.14M -38.79M -36.14M -68.16M -4.56B -69.55M -467M -181M -2.24B -180M -176M -7.79B
Net Debt -85M -74.63M -68.69M -64.01M -121M -8.08B -123M -826M -320M -3.97B -319M -312M -13.81B -
Logo Aquestive Therapeutics, Inc.
Aquestive Therapeutics, Inc. is a pharmaceutical company. The Company is engaged in developing orally administered and topical gel products to deliver complex molecules, providing novel alternatives to invasive and inconvenient standard of care therapies. It has four commercialized products marketed by the Company’s licensees in the United States and around the world and is the manufacturer of these licensed products. The Company also collaborates with pharmaceutical companies to bring new molecules to market using proprietary technologies, including PharmFilm, and has proven drug development and commercialization capabilities. The Company is advancing a late-stage proprietary product candidate for the treatment of severe allergic reactions, including anaphylaxis, and an early-stage epinephrine prodrug topical gel product candidate for various possible dermatology conditions. Its portfolio includes Anaphylm, AQST-108, Libervant, Suboxone, and Emylif.
Employees
147
Date Price Change Volume
01/07/26 $4.240 +1.92% 1,262,774
30/06/26 $4.160 0.00% 1,489,557
29/06/26 $4.160 -5.24% 3,293,950
26/06/26 $4.390 -1.68% 7,384,747
25/06/26 $4.465 -10.52% 5,171,645
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
4.240USD
Average target price
8.889USD
Spread / Average Target
+109.64%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AQST Stock